11-12 September 2018 //  Lancaster Royal Hotel, London


Behnam Ahmadian Baghbaderani

Dr Behnam Ahmadian Baghbaderani

Head of Cell Therapy Development, Lonza

Dr. Behnam Baghbaderani is the head of Cell Therapy Development, Emerging Technologies at Lonza. He has over 14 years of experience in bioengineering and custom manufacturing for cell therapy application. Dr. Baghbaderani holds a PhD degree in Biomedical Engineering from the University of Calgary (Calgary, Canada), where he developed bioreactor protocols for large-scale expansion of human neural stem cells for clinical applications. He completed nearly three years postdoctoral program including a two-year postdoctoral fellowship at the National Institutes of Health (NIH) / National Institute of Neurological Disorders and Stroke (NINDS). His postdoctoral research at the NIH focused on generation of human induced pluripotent stem cells (hiPSCs), bioprocessing of both human embryonic stem cells and hiPSCs and controlled differentiation into neuronal lineage. Since joining Lonza in 2011, he has been working on developing new technologies and manufacturing processes around human pluripotent stem cells, adult stem cells, and CAR-T applications. As the head of CT Development, Dr. Baghbaderani is currently leading the process development and bioassay services, focusing on the development of cGMP compliant processes and cell characterization assays for allogeneic and autologous cell therapy applications.



2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad